Liquidambaric acid
(Synonyms: 路路通酸; Betunolic acid; Liquidambaric acid; (+)-Betulonic acid) 目录号 : GN10522
A triterpenoid
Cas No.:4481-62-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Betulonic acid belongs to the pentacyclic triterpenic derivative class, has antitumor activities.In vitro: BEA-NP is found over three-times more permeable than that solubilized by DMSO in Caco-2 cell monocultures.[1]In vivo: The tumor growth in the S180 berry mice orally doses with BEA-NP at 75 mg/kg is inhibited by 50%. Rubusoside is effective in solubilizing BEA, maintaining its cytotoxicity, enhancing its permeability and reducing tumor growth when orally administered.[1] antitumor activities against MGC-803, PC3, Bcap-37, A375, and MCF-7 human cancer cell lines In vivo: The animals are treated with betulonic acid amide (50 mg/kg in Tween aqueous solution) and heptral (6 mg/kg) as hepatoprotective compounds. It is found that betulonic acid amide stimulats the regenerative response in hepatocytes under conditions of combined toxic exposure and promots recovery of their qualitative and quantitative characteristics. [2]
References:
[1]. Zhang J et al. Employing rubusoside to improve the solubility and permeability of antitumor compound betulonic acid. Nanomedicine (Lond). 2016 Oct 19.
[2]. Semenov DE et al. Hepatoprotective properties of betulonic acid amide and heptral in toxic liver injury induced by carbon tetrachloride in combination with ethanol.Bull Exp Biol Med. 2015 Jan;158(3):336-41.
| Cas No. | 4481-62-3 | SDF | |
| 别名 | 路路通酸; Betunolic acid; Liquidambaric acid; (+)-Betulonic acid | ||
| 化学名 | (1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-prop-1-en-2-yl-2,3,4,5,6,7,7a,10,11,11b,12,13,13a,13b-tetradecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid | ||
| Canonical SMILES | CC(=C)C1CCC2(C1C3CCC4C5(CCC(=O)C(C5CCC4(C3(CC2)C)C)(C)C)C)C(=O)O | ||
| 分子式 | C30H46O3 | 分子量 | 454.69 |
| 溶解度 | ≥ 12.42 mg/mL in DMSO with gentle warming, ≥ 24.27 mg/mL in EtOH with gentle warming | 储存条件 | Store at 2-8°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1993 mL | 10.9965 mL | 21.993 mL |
| 5 mM | 0.4399 mL | 2.1993 mL | 4.3986 mL |
| 10 mM | 0.2199 mL | 1.0997 mL | 2.1993 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。